Pharmacokinetic studies on CI-981 (1) - Absorption, distribution and excretion in rats following single oral or intravenous administration

Japanese Pharmacology and Therapeutics

Volumn 26, Issue 7, 1998, Pages 65-77

  Nemoto, Hiroyuki ^a   Ebine, Hiroki ^a   Ohzone, Yoshihiro ^a   Jin, Yoshitaka ^a   Esumi, Yoshio ^a   Kaneko, Kiyohisa ^b   Watanabe, Masako ^b   Oishi, Shimako ^c  

^a DAIICHI PURE CHEMICALS CO LTD   (Japan)

^b Parke Davis Pharmaceuticals   (Japan)

^c INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

Author keywords

Absorption; Antihyperlipidemic agent; Atorvastatin; CI 981; Distribution; Excretion; HMG CoA reductase inhibitor; Rat

Indexed keywords

ATORVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0031664847     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bocan TMA et al: Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981; Comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1123: 133-144, 1992
2. Krause BR, Newton RS: Lipid-lowering activity of atorvastatin and lovastatin in rodent species; Triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117: 237-244, 1995
3. Bakker-Arkema RG et al: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128-133, 1996
4. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group: Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 79: 1248-1252, 1997
5. Michniewicz BM et al: In vitro and in vivo metabolism of atorvastatin (CI-981). Sixth North American ISSX Meeting, Raleigh, NC, USA, Abstract No. 93, 1994
6. Krause BR et al: In vitro and in vivo activities of atorvastatin metabolites. Warner-Lambert Co. (Ann Arbor, MI, USA), 1995
7. Sirtori CR: Tissue selectivity of hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmac Ther 60: 431-459, 1993
8. Roth BD et al: Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem 34: 463-466, 1991
9. Bergstrom JD et al: Responses to the inhibition of HMG-CoA reductase; A comparison of simvastatin and atorvastatin. Atherosclerosis 134: 121, 1997
10. Naoumova RP et al: Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. Atherosclerosis 134: 130, 1997